Cargando…
Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824702/ https://www.ncbi.nlm.nih.gov/pubmed/29503852 http://dx.doi.org/10.1186/s41181-017-0030-z |
| _version_ | 1783302070749626368 |
|---|---|
| author | Dalm, Simone U. de Jong, Marion |
| author_facet | Dalm, Simone U. de Jong, Marion |
| author_sort | Dalm, Simone U. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5824702 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58247022018-02-28 Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? Dalm, Simone U. de Jong, Marion EJNMMI Radiopharm Chem Letter to the Editor Springer International Publishing 2017-09-29 /pmc/articles/PMC5824702/ /pubmed/29503852 http://dx.doi.org/10.1186/s41181-017-0030-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Letter to the Editor Dalm, Simone U. de Jong, Marion Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title | Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title_full | Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title_fullStr | Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title_full_unstemmed | Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title_short | Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? |
| title_sort | comparing the use of radiolabeled sstr agonists and an sstr antagonist in breast cancer: does the model choice influence the outcome? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824702/ https://www.ncbi.nlm.nih.gov/pubmed/29503852 http://dx.doi.org/10.1186/s41181-017-0030-z |
| work_keys_str_mv | AT dalmsimoneu comparingtheuseofradiolabeledsstragonistsandansstrantagonistinbreastcancerdoesthemodelchoiceinfluencetheoutcome AT dejongmarion comparingtheuseofradiolabeledsstragonistsandansstrantagonistinbreastcancerdoesthemodelchoiceinfluencetheoutcome |